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Summary 
Rationale  
There is evidence that lung function in infancy predicts childhood wheeze. However, very few 
studies have both measured premorbid lung function in early infancy and considered 
clinically significant childhood wheeze phenotypes. Consequently, it is unclear whether early 
lung development is most closely associated with atopic or non-atopic preschool wheeze. 
Objective 
To examine the association between premorbid infant lung function and preschool wheeze 
according to atopic or non-atopic wheeze phenotype.  
Methods  
Infant lung function was measured in 147 healthy term infants aged 5-14 weeks. Rapid 
thoracoabdominal compression was performed during tidal breathing and at raised volume to 
measure maximal expiratory flow at functional residual capacity (V’maxFRC) and forced 
expiratory volume in 0.4 sec (FEV0.4). Atopic status was determined by skin prick testing at 3 
years and wheeze ascertained from parental questionnaires (1 and 3 years).  
Measurements and Main Results  
Lower early infancy V’maxFRC was associated with wheeze in both the first and third years of 
life (p=0.002 and p=0.006, respectively). Lower early infancy FEV0.4 was associated with 
wheeze in infancy (p=0.03). Compared to non-atopic children who did not wheeze, non-
atopic children who wheezed in their third year of life had lower FEV0.4, (p=0.02), whilst 
atopic children who did and did not wheeze had similar FEV0.4 (p=0.4).  
Conclusions 
Lower premorbid infant lung function was present in infants who subsequently wheezed 
during the first and third years of life. Lower FEV0.4 in early infancy was associated with non-
atopic wheeze but not atopic wheeze at 3 years of age.  
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 1 
Introduction 
Lower infant lung function is a risk factor for wheeze in infancy and early childhood1-5. 
Previous studies have demonstrated abnormalities of infant lung function are present in those 
children who subsequently experience wheeze and these abnormalities can be detected prior 
to the first wheezing illness1-4. The results of longer-term follow up studies are less consistent. 
Although tracking of lung function from infancy, through childhood6 and into adult life7 is 
well described, the relationship between early lung function and phenotypes of wheezing 
illness is less clear. The Tucson study, for example, found reduced V’maxFRC to be associated 
with a transient wheeze phenotype in 125 infants assessed at a mean age 2.4 months (SD 2 
months), but no association was found with wheezing after 3 years of age8. In contrast, other 
studies suggest early impairment of lung function is a risk factor for wheeze which persists 
into later childhood6:9.  
 
The original ‘wheeze phenotypes’ described in the Tuscon study were defined retrospectively 
according to age of onset and persistence of symptoms8. More recently, work has been 
undertaken to determine clinical phenotypes10;11 and to consider whether early abnormalities 
of lung function are associated with childhood wheeze phenotypes based upon clinical 
features. Infants with recurrent wheeze considered at high risk of subsequent asthma due to 
either a parental history of asthma or personal history of eczema, allergic rhinitis, wheezing 
without a cold and/or serum eosinophilia have been found to have lower forced expiratory 
volumes at 8-20 months than healthy controls or wheezy infants at lower risk of subsequent 
asthma12. This study suggests early impairment of lung function is associated with preschool 
wheeze and particularly so in the presence of markers of atopic sensitisation. However, 
premorbid infant lung function was not measured and the relationship between lung function 
and clinical wheeze phenotype according to atopy was not established in an unselected 
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population. Whilst it is clear that both early lung function and atopic status are important 
determinants of preschool wheeze it is not clear how premorbid infant lung function relates to 
the atopic and non-atopic wheeze phenotypes. 
 
Premorbid infant lung function may reflect early environmental or genetic influences. 
Common genetic polymorphism is known to impact neonatal disease and outcome13. 
ADAM33 is a positionally cloned asthma susceptibility gene that shows strongest linkage 
with a combined asthma and bronchial hyperresponsiveness phenotype14. ADAM33 is 
expressed in lung fibroblasts and bronchial smooth muscle and is expressed during embryonic 
lung development15. Previously, ADAM33 polymorphisms have been associated with 
impaired lung function at 3 years of age, specifically deficits in FEV1 and carriers 
homozygous for the A allele of F+1 SNP had double the risk of transient early wheeze16. 
Associations between a number of individual SNPs and both baseline lung function and non 
atopic asthma have also been demonstrated in a population of German school children17.  
 
The Southampton Women’s Survey (SWS) was the first to measure premorbid FEV0.4 in a 
longitudinal pregnancy cohort study18. The rapid thoracoabdominal compression (RTC) 
technique has been used for many years to measure V’maxFRC in infants. Concerns about 
intersubject and intrasubject variability led to a modification of the method, performing the 
manoeuvre at raised volume (RV-RTC), removing the use of a variable volume landmark19. It 
has been suggested that measurement of FEV0.5 using RVRTC is more sensitive at detecting 
impaired airway function than V’maxFRC in infants with CF prior to respiratory symptoms20;21. 
This is the first study to investigate the predictive value of infant FEV0.4 in healthy term 
infants in relation to future wheeze. Using this outcome measure, we aimed to test the 
hypothesis that lower infant lung function is associated with preschool wheeze and to explore 
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the associations between premorbid infant lung function and preschool wheeze according to 
atopic phenotype. As a secondary aim, we explored the relationship between ADAM33 
polymorphism, lung function in infancy and preschool wheeze. 
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Methods 
Participants 
The Southampton and South West Hampshire Local Research Ethics Committee approved the 
protocol and written consent was obtained from the children’s mothers. Detailed information 
regarding the participants and infant lung function testing have been described18. In brief, 
Caucasian infants, born at least 37 weeks gestation without major congenital anomalies and 
prior to any respiratory infection were recruited from the SWS, a population-based pregnancy 
cohort22. 362+ women were approached about the study; 219+ (60%) declined. Of those who 
agreed to participate 12+ (3%) were excluded because of recent upper respiratory tract 
infection or other illness; the majority of those declining did so due to concerns about 
sedation and respiratory infection was not a common reason for declining to participate. Lung 
function was measured, between May 1999 and October 2002, when the infants were 5-14 
weeks old. 
  
Lung function was measured, with infants lying supine, in quiet sleep augmented with chloral 
hydrate (75-100 mg/kg). An inflatable jacket connected to a rapid inflation system was placed 
around the infant’s chest and abdomen and a leak-free facemask with Fleisch 
pneumotachograph (Dynasciences, Blue Bell, CA) was held over the nose and mouth. Data 
were collected using RASP software (Physiologic Ltd, Newbury, Berks, UK) and analysed in 
SQUEEZE (Paul Dixon, London).  
 
As previously described18, respiratory rate was measured during tidal breathing. To record 
partial expiratory flow volume curves, a stable end expiratory level was established before 
performing an RTC at the lowest pressure to achieve the best V’maxFRC, calculated from the 
partial expiratory flow volume curve. Passive, relaxed inflations to 30cm water were recorded 
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using a resuscitator connected to the pneumotachograph. The airway opening pressure was 
measured during occlusion which causes the respiratory muscles to relax by the Hering 
Breuer reflex and airway pressure to equilibrate with alveolar pressure; this in turn represents 
the summed elastic recoil pressure of the lung and chest wall. Compliance of the respiratory 
system (Crs) was calculated using SQUEEZE from the resultant passive flow–volume curves 
as change in volume for unit of airway outlet pressure (ml/mm water). Raised volume RTC 
curves were recorded at the optimal jacket pressure at the end of a passive inspiration using a 
technique adapted from Feher and colleagues19, and FEV0.4 and FVC were measured from the 
forced expiratory flow–volume curve.  
 
For each infant, FEV0.4 and Crs were calculated from the ‘best’ raised volume loop (greatest 
sum of FEV0.4 and FVC) and the best V’maxFRC was used. At least two acceptable, 
reproducible (within 10%) raised volume and partial expiratory curves were obtained. It was 
not possible to record valid data in every infant for each measure of lung function, there were 
approximately 100 infants with acceptable lung function data for each measurement. 
 
Symptoms 
Mothers completed contemporaneous respiratory symptom diaries during their child’s first 
year of life. Symptoms were explained to each mother by the infant lung function nurses. A 
new diary was posted every 3 months, followed up by a reminder phone call from a nurse of 
the infant lung function study team. For each 24hr period parents recorded daytime and night 
time wheeze. At ages one and three years mothers completed a nurse-administered 
questionnaire which included the question ‘has your child experienced any episodes of 
chestiness associated with wheezing or whistling in his/her chest since they were last seen?’. 
Skin reactivity to cata, doga, house dust mitea (Dermatophagoides pteronyssinus), milka, grass 
 6 
pollensa, and eggb was assessed at age 3 years (Hollister-Stier, Spokane, WAa, Alyostal, 
Antony, Franceb). Atopy was defined as a wheal to any allergen at least 3mm in diameter in 
the presence of a wheal of at least 3 mm in diameter to 10 mg/ml histaminea solution and no 
response to 50% glycerina.  
 
Genotyping 
DNA was isolated from cord blood using a salting-out procedure23. The following five SNPs 
were chosen for genotyping as they span the ADAM33 gene region (based on the LDU map 
from Simpson et al16). ADAM33 SNPs Bp1 (rs487377), Fp1 (rs511898), STp7 (rs574174), 
Vm3 (rs628977), V4 (rs2787094) were genotyped by TaqMan SNP genotyping assays (E-
Table1). 
 
Statistical Analysis 
The infant lung function data were logarithmically transformed to achieve normality and 
adjusted for age and sex where necessary. t-tests were used to assess differences between 
geometric mean group values of infant lung function measurements according to wheeze 
status at 1 and 3 years, and after subdividing the 3-year wheeze group according to atopic 
status. Agreement between the parent-completed symptom diaries and the nurse-administered 
questionnaires was assessed by weighted Kappa (κ) analysis. ADAM33 haplotype 
quantitative trait and power analysis were performed using Haploscore (Haplo.stats R 
package version 1.3.8.)24 in R (version 2.5.1)25 with the additive haplotype effect model.  
 
Assuming 50 children in each outcome group, there was 80% power at the 5% level of 
significance to detect a difference of 0.57 SDs in any infant lung function measurement 
between the two outcome groups.  
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Results 
147 infants had lung function measurements, of which 146 provided questionnaire data at age 
one year, 141 provided questionnaire data at 3 years of age and 113 had skin prick testing. 
Symptom diaries were returned by 102 mothers. There was strong concordance between the 
prospective symptom diaries and retrospective questionnaires with respect to classification of 
children according to presence or absence of wheeze during the first year of life, (κ =0.71, 
p<0.001). Given this, all subsequent analyses are based upon questionnaire data. A total of 
114 DNA samples were available for ADAM33 SNP genotyping; genotype assignment 
approached 99% (6 failed PCR reactions out of a total 570) with a maximum of two 
unassigned genotypes for each SNP and all genotype frequencies were in Hardy-Weinberg 
Equilibrium. Matched genotype and lung function data were available for 103 children for 
respiratory rate, 82 for Crs, 105 for V’maxFRC and for 76 children for FEV0.4. (See online 
supplement).  
 
During the first year of life, 74 infants had at least one episode of wheezing. Thirty three 
children experienced wheeze in the third year of life, of these 23 had also experienced wheeze 
in the first year of life whilst 10 had not. Of the 113 children who were skin prick tested for 
allergy, 20 (17.7%) had at least one positive reaction and were classed as atopic. Of the 
children who experienced wheeze 25% were atopic and 75% were not. 
 
The demographic characteristics of those children reporting wheeze at 3 years and those that 
did not are listed in table 1. Comparing children who did and did not wheeze, there were no 
differences in gender or the mother’s age, atopy but those who wheezed at 3 years were more 
likely to have a mother who smoked during pregnancy. However, those who wheezed in the 
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first year of life were more likely to be born to younger mothers and have mothers who had 
smoked in pregnancy than those who did not wheeze (data not shown).  
 
Associations between wheeze or wheeze phenotype and lung function were examined after 
adjusting for factors that were found to influence measures of lung function on univariate 
analysis. FEV0.4, and V’maxFRC were adjusted for gender and Crs for gender and age at testing. 
 
Relationship between infant lung function and respiratory symptoms reported at age 1 year 
V’maxFRC, FEV0.4 and Crs were lower in infants who subsequently wheezed in their first year 
than in those who did not by 22.5% (p=0.002), 8.1% (p=0.03) and 6.8% (p=0.04) respectively 
(Table 2). The group mean respiratory rate was 6.8% higher in the wheeze group than in the 
non-wheeze group (p=0.03). 
 
Relationship between infant lung function and respiratory symptoms reported at age 3 years 
V’maxFRC was 23.2% lower in infants who wheezed in their third year than in those who did 
not (Table 2) (p=0.006). However, there were only small non-significant differences in 
FEV0.4, Crs and respiratory rate between the two groups. When non-atopic children were 
considered separately from atopic individuals, FEV0.4 was 11% lower in those who wheezed 
(p=0.02) (Table 3). There were no significant differences in any measure of infant lung 
function when atopic children with wheeze in the third year were compared to non-atopic 
children without wheeze (Table 3).  
 
ADAM33 SNP haplotype analysis 
No ADAM33 SNP haplotype was significantly associated with infant lung function 
measurements after adjusting for multiple testing by Bonferroni correction (E-Table3). 
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Haplopower analysis (Online Data Supplement) revealed that with the small sample size (n = 
82) we were underpowered (Power = 19%) to detect a common haplotype (freq = 18%) 
association accounting for 5% of the variance in the mean of the Crs measurement.  
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Discussion 
This study demonstrates an association between impaired premorbid infant lung function and 
preschool wheezing illness. This confirms the results of previous studies4;5. Our analyses 
show for the first time that lower lung function in early infancy is a risk factor for non-atopic 
wheeze, rather than atopic wheeze. Additionally, this study is the first to report reduced 
FEV0.4, prior to lower respiratory infection, as a risk factor for wheeze in the preschool years. 
This is particularly important in view of recent work demonstrating that diminished timed 
forced expiratory volumes are an important predictor of all-cause mortality in adult life26. As 
with other studies of infant lung function, this study is of low power due to the heavy 
technical investment required to produce high quality measurements. 
 
Premorbid measures of forced expiratory volume in 0.4 seconds (FEV0.4) during infancy as a 
predictor of wheeze have not previously been studied, though reduced FEV0.5 following 
symptoms has been reported in wheezy children aged 8 – 20 months12. Lung function 
measures derived from raised volume expiratory manoeuvres are believed to discriminate 
better between healthy individuals and those with respiratory disease when compared to tidal 
breathing measures19;20. FEV0.4 is derived from measurement of expiratory flow from close to 
total lung capacity and is not dependent upon a volume landmark. This is more repeatable 
than measurement at FRC as the FRC of infants can vary on a breath by breath basis, FEV0.4 
provides a more robust measure of infant lung function than V’maxFRC27. Furthermore, FEV0.4 
is well suited to longitudinal study as it is intuitively more comparable to the measures of lung 
function, such as FEV1, which are used in older children and adults. 
  
The results of this study are of relevance to the general population. We recruited healthy 
infants and only excluded those born before 37 weeks gestation to prevent bias due to effects 
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of prematurity upon lung development. Our results demonstrate that variations in measures of 
expiratory flow measured in unselected populations are associated with preschool wheeze. 
 
Small study numbers limited the exploration of lung function measures according to wheeze 
phenotype. However, a significant difference in FEV0.4 was noted in non-atopic children who 
wheezed during the third year of life compared to non-atopic children without wheeze. There 
was no difference in any measure of infant lung function when atopic children with wheeze in 
the third year were compared to non-atopic children without wheeze. This may have been 
partly related to greater power associated with a more balanced distribution of non-atopic than 
atopic individuals between the wheeze and no wheeze groups. However, others have 
speculated that wheezing during the first year of life is often a transient condition due to 
reduced airway caliber and that wheeze beginning or persisting into later childhood is more 
likely to be due to the wheeze phenotype recognised as asthma4.  
 
Due to the number of subjects studied it was not possible to analyse our data according to age 
of onset. However, the broader confidence intervals and divergence of results between atopic 
and non-atopic individuals at age three years may be evidence of comparative heterogeneity 
of wheeze phenotypes later in childhood. The strong association between reduced measures of 
forced expiratory flow and wheeze at one year may reflect a common underlying mechanism, 
similar to that proposed by Martinez, whereby initial airway diameter, length or other 
characteristics might predispose certain infants to wheezing with viral respiratory infections3. 
With growth this may resolve in some infants as airway size increases but for those with the 
smallest airway dimensions the risk of non-atopic wheeze may persist. In contrast, airway 
dimensions at birth may be less significant in the aetiology of atopic wheeze compared to 
other factors acquired in association with an atopic phenotype. 
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As described earlier, ADAM33 is expressed in the embryonic lung15 and SNPs in the gene 
encoding ADAM33 were previously found to predict impaired lung function at age 3 and 5 
years16. However, it is unclear whether ADAM33 polymorphism is associated with abnormal 
lung function at birth (reflecting altered in utero lung development) or whether post-natal 
gene-environment interaction alters lung function and increases risk of asthma. Recent 
observations from the PIAMA birth cohort show that in utero, but not post natal, cigarette 
smoke exposure interacts with ADAM33 polymorphism to determine childhood lung function 
and BHR would suggest that ADAM33 polymorphism may alter in utero lung development28. 
In the current study, no ADAM33 haplotype was associated at the 5% level with lung 
function or symptoms in the first or third years of life after correction for multiple testing. 
Simpson et al. described that the F+1 polymorphism explained 3% of the variance in lung 
function (sRaw) at 3 years of age16; power calculations show that we only had 19% power to 
detect an association that predicts 5% variance in Crs measurements. Given the observation of 
interaction with in utero smoke exposure and the trend towards association seen in the current 
study, the association between ADAM33 haplotypes and infant lung function needs to be 
examined in a meta-analysis of data from all available infant lung function cohorts. 
 
Strengths and limitations of this study 
We successfully measured infant lung function in 147 infants; the robust FEV0.4 measurement 
was recorded in 98 infants, and 141 children (96%) were followed up to age 3 years. 
Although the number of infants recruited to this study was small it is comparable to the 
numbers recruited to similar cohort studies4;5. The numbers involved precluded adjustment for 
multiple confounders or subgroup analysis. For example, although some studies have found 
evidence of reduced early lung function in infants whose mothers smoked29;30, it was not 
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feasible to stratify for maternal smoking. Moreover, maternal smoking was not considered a 
confounder of the relationship between infant lung function and later wheeze as we have 
previously demonstrated that infant lung function is not significantly associated with maternal 
smoking in our cohort18. A second source of potential bias relates to exclusion of children on 
the basis of respiratory infection prior to lung function measurement. This exclusion was used 
to ensure that the effects of premorbid lung function upon later wheeze status were explored 
and to avoid bias by postnatal effects. This would only bias the result if the relationship 
between infant lung function and later wheeze differed between those infants who 
experienced early infection and those who did not. There is no reason to believe that this 
relationship would differ in a manner which would decrease the strength of the association 
between poor infant lung function and later wheeze; that is to say it is unlikely infants 
suffering early respiratory infection would have a better outcome in terms of later wheeze 
than those that did not experience early infections.  
 
In summary this study has shown a significant relationship between early life lung function 
and respiratory symptoms in the first and third years of life. Lower FEV0.4 in early infancy 
was associated with non-atopic wheeze but not atopic wheeze at 3 years of age. This is further 
evidence suggesting that pre-natal factors contribute to the development of wheeze in early 
life.  
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Figure 1 Flow diagram of recruitment process and follow up 
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Tables 
 
 
Table 1 Characteristics of those children reported to wheeze at 3 years of age compared 
to those who were not 
 
 
 
Children not reported 
to wheeze at 3 years 
(n=108) 
Children reported to 
wheeze at 3 years 
(n=33) 
P-value 
Maternal age at child’s birth (years), 
mean (SD) 
30.3 (3.3) 29.7 (4.2) 0.3 
Maternal smoking during pregnancy, 
(%) 
12.3 27.3 0.04 
Male gender, (%) 49.1 54.6 0.6 
Maternal atopy, (%) 43.3 48.3 0.6 
 
 1 
Table 2 Infant lung function measures by whether the infant wheezed or not in the first and in the third year of life 
 One year of age Three years of age 
 No wheeze  Wheeze  Reduction/increase in 
those who wheezed  
No wheeze  Wheeze  Reduction/increase in 
those who wheezed  
 Mean, (95% CI) n Mean, (95% CI) n %, (95% CI) Mean, (95% CI) n Mean, (95% CI) n %, (95% CI) 
V’maxFRC*
 149.0, (133.3 to 166.5) 70 115.4, (103.3 to 129.0) 72 -22.5%, (-33.7% to -9.5%) 139.2, (126.5 to 153.1) 106 106.8, (93.0 to 122.7) 32 -23.2%, (-36.4 % to -7.3%) 
FEV0.4** 143.3, (136.4 to 150.7) 49 131.8, (124.0 to 140.1) 49 -8.1%, (-15.0% to -0.6%) 139.6, (133.8 to 145.7) 73 128.6, (118.4 to 139.6) 25 -7.9%, (-15.5% to 0.3%) 
Crs*** 49.4, (47.3 to 51.6) 52 46.0, (43.7 to 48.5) 56 -6.8%, (-12.8% to -0.3%) 48.0, (46.2 to 49.8) 79 46.8, (43.1 to 50.7) 29 -2.5%, (-9.8% to 5.4%) 
Respiratory 
rate 
(breaths/min) 
42.8, (41.1 to 44.5) 69 45.7, (43.8 to 47.7) 72 6.8%, (0.8% to 13.1%) 44.1, (42.6 to 45.7)  106 45.2, (42.9 to 47.7) 31 2.5%, (-4.6% to 10.1%) 
 
* Maximal expiratory flow at functional residual capacity (ml/s), adjusted for age 
** Forced expiratory volume in the first 0.4 seconds of expiration (ml), adjusted for age 
*** Respiratory system compliance (ml/mm water), adjusted for age and sex 
Results are geometric mean values. Percentage increase is calculated from the logged values of the respiratory measures 
 
 1 
Table 3 Infant lung function measures by whether the infant wheezed and their atopy status in the third year of life  
 No wheeze and no atopy  Wheeze and no atopy Reduction/increase in 
those who wheezed but 
were not atopic 
Wheeze and atopy Reduction/increase in 
those who wheezed and 
were atopic 
 Mean, (95% CI) n Mean, (95% CI) n %, (95% CI) Mean, (95% CI) n %, (95% CI) 
V’maxFRC*
 135.0, (119.8 to 152.1) 71 107.1, (87.5 to 131.1) 20 -20.6%, (-37.9% to 1.5%) 108.5, (87.1 to 135.2) 7 -19.6%, (-45.3% to 18.1%) 
FEV0.4* 139.0, (132.2 to 146.2) 49 123.7, (114.6 to 133.5) 16 -11.0%, (-19.2% to -2.0%) 148.9, (110.1 to 201.3) 5 7.1%, (-9.6% to 26.9%) 
Crs** 48.6, (46.4 to 51.0) 56 45.8, (41.3 to 50.9)  19 -5.8%, (-14.7% to 4.1%) 51.8, (45.5 to 59.0) 6 6.5%, (-8.2% to 23.6%) 
Respiratory 
rate 
(breaths/min) 
45.5, (43.4 to 47.6) 71 43.8, (40.6 to 47.2) 20 -3.7%, (-12.3% to 5.7%) 49.1, (45.0 to 53.5) 6 7.9%, (-7.8% to 26.3%) 
 
* Maximal expiratory flow at functional residual capacity (ml/s), adjusted for age 
** Forced expiratory volume in the first 0.4 seconds of expiration (ml), adjusted for age 
*** Respiratory system compliance (ml/mm water), adjusted for age and sex 
Results are geometric mean values. Percentage increase is calculated from the logged values of the respiratory measures 
